Protalix BioTherapeutics (PLX) Non Operating Interest Expenses (2013 - 2025)

Protalix BioTherapeutics has reported Non Operating Interest Expenses for 13 years, with the latest figure at $6000.0 in Q1 2025.

• On a quarterly basis, Non Operating Interest Expenses fell 98.46% year-over-year to $6000.0 in Q1 2025; TTM through Mar 2025 was $678000.0, a 76.85% decrease from a year earlier, with the FY2024 full-year figure at $1.1 million, down 66.6% from the prior year.
• Non Operating Interest Expenses was $6000.0 for Q1 2025 at Protalix BioTherapeutics, roughly flat from $6000.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $2.4 million in Q3 2021, with the low at $6000.0 in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is $850764.7, with a median of $639000.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses surged 109.47% in 2023, then sank 99.22% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $908000.0 in 2021, then fell by 28.41% to $650000.0 in 2022, then climbed by 19.08% to $774000.0 in 2023, then tumbled by 99.22% to $6000.0 in 2024, then changed by 0.0% to $6000.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $6000.0 (Q1 2025), $6000.0 (Q4 2024), and $299000.0 (Q3 2024), per Business Quant data.